CPT11

(redirected from Irinotecan)
Also found in: Medical, Wikipedia.
AcronymDefinition
CPT11Irinotecan (chemotherapy drug)
References in periodicals archive ?
Standard first-line treatments including fluorouracil (5-FU) with leucovorin (LV) and irinotecan or oxaliplatin, alone or combined with bevacizumab, have resulted in a median overall survival (mOS) greater than 20 months [3-9].
Therefore, AHCC is safe and unlikely to result in increased toxicity when used in combination with commonly used chemotherapeutic agents such as Cyclophosphamide, Ifosfamide, Paclitaxel, Docetaxel, Irinotecan, Vincristine, interferon and Imatinib.
More patients with wild-type KRAS tumors responded to cemximab (Erbitux) plus the FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy regimen (59%) than to FOLFIRI alone (43%), reported Dr.
In the Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) trial, 1,298 patients who had failed one previous round of chemotherapy were randomized to receive either irinotecan alone or irinotecan plus cetuximab.
ScinoPharm (Tainan, Taiwan) was awarded a United States patent that relates to the preparation of SN-38, a key intermediate in the synthesis of irinotecan. United States Patent 7,151,179, entitled "Process for the Preparation of 7-Alkyl-10-Hydroxy-20(S)- Camptothecin," was issued on December 19, 2006 by the United States Patent and Trademark Office.
Tokyo, Japan, May 19, 2006 - (JCN) - Yakult Honsha announced on May 18 that it will develop a liposomal formulation of irinotecan, a kind of anticancer agent, with Terumo.
We previously reported that genetic polymorphisms of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene were significantly related to severe toxicity of irinotecan (1).
Data from the international trial also reveal that patients given FOLFOX 4 experienced less severe diarrhea, vomiting, and hair loss than those on standard IFL (irinotecan, 5-fluorouracil and leucovorin) treatment.
In these people, irinotecan induces a sharp drop in white blood cell count, a side effect that opens the door to infections.
PG490-88Na appeared in those preclinical studies to have direct anti-cancer effects, and to potentiate effects of commonly prescribed chemotherapy drugs such as 5-FU, Camptosar (irinotecan) and Taxol (paclitaxel).
The Food and Drug Administration (FDA) today announced the approval of Eloxatin (oxaliplatin) injection for use in combination with infusional 5-fluorouracil (5-FU) and leucovorin for the treatment of patients with colorectal cancer whose disease has recurred or become worse following initial therapy with a combination of irinotecan with bolus 5-FU and leucovorin.
Irinotecan is not recommended for routine first-line treatment but can have limited use in second-line treatment of the disease, Nice said.